Key result
Tailored prasugrel use in ACS-PCI is linked to a ~2% one-year death or MI rate.
Why the study?
The 1-year outcomes of routine prasugrel treatment after ACS in a large-scale registry were not well established.
Does a tailored approach of routine prasugrel treatment improve 1-year ischemic and bleeding outcomes in patients with acute coronary syndromes treated with percutaneous coronary intervention?
Observational (n=4,258)
Yes
Does a tailored approach of routine prasugrel treatment improve 1-year ischemic and bleeding outcomes in patients with acute coronary syndromes treated with percutaneous coronary intervention?
In routine clinical practice, a tailored approach to prasugrel prescription in ACS patients undergoing PCI is associated with low rates of ischemic and bleeding events at 1 year.
Answers are grounded in this paper and cite their sources.
Tailored prasugrel after ACS-PCI was associated with low ischemic and bleeding rates; leaves open superiority over clopidogrel in unselected real-world populations.
OBJECTIVE: To investigate 1‑year outcomes with routine prasugrel treatment after acute coronary syndrome (ACS) in a large-scale registry. METHODS: The Rijnmond Collective Cardiology Research registry is a prospective, observational study that enrolled 4,258 consecutive ACS patients treated with percutaneous coronary intervention (PCI) with 1‑year follow-up. Patients received prasugrel as first-choice antiplatelet agent, except for increased bleeding risk patients in which clopidogrel was recommended. Events were validated by an independent clinical endpoint committee. RESULTS: A total number of 2,677 patients received prasugrel at discharge after the index event. Eighty-one percent of the target population was on prasugrel treatment at hospital discharge. At 1 year, the primary endpoint, a composite of all-cause mortality and myocardial infarction, occurred in 2.4% of patients receiving prasugrel. All-cause mortality occurred in 1.0%, myocardial infarction in 1.5%, target-vessel revascularisation in 3.1%, stent thrombosis in 0.6%, and stroke in 0.5% of the patients treated with prasugrel. Thrombolysis in Myocardial Infarction defined major bleeding episodes not related to coronary artery bypass grafting were observed in 1.4% of patients receiving prasugrel. CONCLUSIONS: In routine practice, a tailored approach of prasugrel prescription in ACS patients undergoing PCI, resulted in low ischaemic and low bleeding rates up to 1 year post PCI.
No takes yet. Share an insight, caveat, or question.
Yetgin et al. (2018) conducted an observational in Acute coronary syndrome (n=4,258). Prasugrel was evaluated on Composite of all-cause mortality and non-fatal myocardial infarction. In routine clinical practice, a tailored approach to prasugrel prescription in acute coronary syndrome patients undergoing percutaneous coronary intervention resulted in a 2.4% rate of all-cause mortality and myocardial infarction at 1 year.
Synapse has enriched 10 related papers. Consider them for comparative context: